Can probiotics modulate human disease by impacting intestinal barrier function?

British Journal of Nutrition

Volumn 117, Issue 1, 2017, Pages 93-107

  Bron, Peter A ^a   Kleerebezem, Michiel ^b   Brummer, Robert Jan ^c   Cani, Patrice D ^d   Mercenier, Annick ^e   MacDonald, Thomas T ^f   Garcia Ródenas, Clara L ^e   Wells, Jerry M ^b  

^a NIZO FOOD RESEARCH   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c Örebro University   (Sweden)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Gastrointestinal disorders; Gut barrier; Gut microbiota; Immunity; Probiotics

Indexed keywords

BACTERIOCIN; CIPROFLOXACIN; METRONIDAZOLE; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MOTILITY; HUMAN; ILEITIS; INFECTION PREVENTION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS INGLUVIEI; LACTOBACILLUS PARACASEI; LACTOBACILLUS SALIVARIUS; MICROBIAL DIVERSITY; NECROTIZING ENTEROCOLITIS; NONHUMAN; OBESITY; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; WEIGHT REDUCTION; ANIMAL; DRUG EFFECTS; INTESTINAL DISEASES; INTESTINE; PHYSIOLOGY;

ANIMALS; HUMANS; INTESTINAL DISEASES; INTESTINES; PROBIOTICS;

EID: 85009999827     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114516004037     Document Type: Review

References (228)

1. Claes IJJ, Garcia CEV & Lebeer S (2015) Novel opportunities for the exploitation of host-microbiome interactions in the intestine. Curr Opin Biotechnol 32, 28-34.
2. van Baarlen P, Kleerebezem M & Wells JM (2013) Omics approaches to study host-microbiota interactions. Curr Opin Microbiol 16, 270-277.
3. Bron PA, van Baarlen P & Kleerebezem M (2012) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10, 66-78.
4. Cani PD (2014) Metabolism in 2013: the gut microbiota manages host metabolism. Nat Rev Endocrinol 10, 74-76.
5. Hill C, Guarner F, Reid G, et al. (2014) Expert consensus document: The International Scientific Association for Pro-biotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506-514.
6. Food and Agriculture Organization/World Health Organization (2002) Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food, London, ON, Canada.
7. Johansson MEV, Larsson JMH & Hansson GC (2011) The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 108, 4659-4665.
8. Loonen LMP, Stolte EH, Jaklofsky MTJ, et al. (2014) REG3y-deficient mice have altered mucus distribution and increased mucosal inflammatory responses to the microbiota and enteric pathogens in the ileum. Mucosal Immunol 7, 939-947.
9. Vaishnava S, Yamamoto M, Severson KM, et al. (2011) The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334, 255-258.
10. Van der Sluis M, De Koning BAE, de Bruijn ACJM, et al. (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117-129.
11. Rossi GA, van Baarlen P & Wells JM (2013) Host-recognition of pathogens and commensals in the mammalian intestine. Curr Top Microbiol Immunol 358, 291-321.
12. Sovran B, Loonen LMP, Lu P, et al. (2015) IL-22-STAT3 pathway plays a key role in the maintenance of ileal homeostasis in mice lacking secreted mucus barrier. Inflamm Bowel Dis 21, 531-542.
13. Hermiston ML & Gordon JI (1995) Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270, 1203-1207.
14. Takahashi N, Vereecke L, Bertrand MJM, et al. (2014) RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95-99.
15. Tanaka H, Takechi M, Kiyonari H, et al. (2015) Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice. Gut 10, 1529-1538.
16. Guenther C, Martini E, Wittkopf N, et al. (2011) Caspase-8 regulates TNF-[agr]-induced epithelial necroptosis and terminal ileitis. Nature 477, 335-339.
17. Kaser A, Lee AH, Franke A, et al. (2008) XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743-756.
18. Nenci A, Becker C, Wullaert A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557-561.
19. Welz PS, Wullaert A, Vlantis K, et al. (2011) FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477, 330-334.
20. Rakoff-Nahoum S, Hao L & Medzhitov R (2006) Role of tolllike receptors in spontaneous commensal-dependent colitis. Immunity 25, 319-329.
21. Vaishnava S, Behrendt CL, Ismail AS, et al. (2008) Paneth cells directly sense gut commensals and maintain home-ostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 105, 20858-20863.
22. Menendez A, Willing BP, Montero M, et al. (2013) Bacterial stimulation of the TLR-MyD88 pathway modulates the homeostatic expression of ileal Paneth cell a-defensins. J Innate Immun 5, 39-49.
23. Liu AY, Destoumieux D, Wong A V, et al. (2002) Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 118, 275-281.
24. Rossi O, Karczewski J, Stolte EH, et al. (2013) Vectorial secretion of interleukin-8 mediates autocrine signalling in intestinal epithelial cells via apically located CXCR1. BMC Res Notes 6, 431.
25. Karczewski J, Troost FJ, Konings I, et al. (2010) Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 298, G851-G859.
26. Gotteland M, Cruchet S & Verbeke S (2001) Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther 15, 11-17.
27. Davitt CJH & Lavelle EC (2015) Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 90, 52-69.
28. Harro C, Chakraborty S, Feller A, et al. (2011) Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol 18, 1719-1727.
29. Bovee-Oudenhoven IMJ, Lettink-Wissink MLG, Van Doesburg W, et al. (2003) Diarrhea caused by enterotoxigenic Escherichia coli infection of humans is inhibited by dietary calcium. Gastroenterology 125, 469-476.
30. Ten Bruggencate SJM, Girard SA, Floris-Vollenbroek EGM, et al. (2014) The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study. Eur J Clin Nutr 69, 385-391.
31. Ouwehand AC, Ten Bruggencate SJM, Schonewille AJ, et al. (2014) Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection. Br J Nutr 111, 465-473.
32. Li S, Huang X li, Sui J zhe, et al. (2014) Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 173, 153-161.
33. Saavedra JM, Bauman NA, Perman JA, et al. (1994) Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344, 1046-1049.
34. Szajewska H, Wanke M & Patro B (2011) Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther 34, 1079-1087.
35. Bujalance C, Jimenez-Valera M, Moreno E, et al. (2014) Lack of correlation between in vitro antibiosis and in vivo protection against enteropathogenic bacteria by probiotic lactobacilli. Res Microbiol 165, 14-20.
36. Corr SC, Li Y, Riedel CU, et al. (2007) Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104, 7617-7621.
37. Johnson-Henry KC, Nadjafi M, Avitzur Y, et al. (2005) Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis 191, 2106-2117.
38. Emara MH, Elhawari SA, Yousef S, et al. (2015) Emerging role of probiotics in the management of Helicobacter pylori infection: histopathologic perspectives. Helicobacter 21, 3-10.
39. Bermudez-Brito M, Munoz-Quezada S, Gomez-Llorente C, et al. (2015) Lactobacillus paracasei CNCM I-4034 and its culture supernatant modulate Salmonella-induced inflammation in a novel transwell co-culture of human intestinal-like dendritic and Caco-2 cells. BMC Microbiol 15, 79.
40. Asahara T, Shimizu K, Takada T, et al. (2011) Protective effect of Lactobacillus casei strain Shirota against lethal infection with multi-drug resistant Salmonella enterica serovar Typhimurium DT104 in mice. J Appl Microbiol 110, 163-173.
41. Zoumpopoulou G, Foligne B, Christodoulou K, et al. (2008) Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and Salmonella infection in murine models. Int J Food Microbiol 121, 18-26.
42. Spees AM, Lopez CA, Kingsbury DD, et al. (2013) Colonization resistance: battle of the bugs or Ménage à Trois with the host? PloS Pathog 9, e1003730.
43. Derrien M & van Hylckama Vlieg JET (2015) Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol 23, 354-366.
44. Cleusix V, Lacroix C, Vollenweider S, et al. (2007) Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol 7, 101.
45. Cotter PD, Hill C & Ross RP (2005) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3, 777-788.
46. Servin AL (2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28, 405-440.
47. Pretzer G, Snel J, Molenaar D, et al. (2005) Biodiversity-based identification and functional characterization of the mannose-specific adhesin of Lactobacillus plantarum. J Bacteriol 187, 6128-6136.
48. Adlerberth I, Ahrne SIV, Johansson ML, et al. (1996) A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environ Microbiol 62, 2244-2251.
49. Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, et al. (2015) The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep 16, 164-177.
50. Klaasen HLBM, Koopman JP, Poelma FGJ, et al. (1992) Intestinal, segmented, filamentous bacteria. FEMS Microbiol Lett 88, 165-179.
51. Altenhoefer A, Oswald S, Sonnenborn U, et al. (2004) The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 40, 223-229.
52. Lu RY, Yang WX & Hu YJ (2014) The role of epithelial tight junctions involved in pathogen infections. Mol Biol Rep 41, 6591-6610.
53. Hodges K & Gill R (2010) Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes 1, 4-21.
54. Asahara T, Shimizu K, Nomoto K, et al. (2004) Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157: H7. Infect Immun 72, 2240-2247.
55. Carey CM, Kostrzynska M, Ojha S, et al. (2008) The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157: H7. J Microbiol Methods 73, 125-132.
56. Castagliuolo I, LaMont JT, Nikulasson ST, et al. (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64, 5225-5232.
57. Lievin-Le Moal V, Amsellem R, Servin AL, et al. (2002) Lacto-bacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut 50, 803-811.
58. Sherman PM, Johnson-Henry KC, Yeung HP, et al. (2005) Probiotics reduce enterohemorrhagic Escherichia coli O157: H7-and enteropathogenic E. coli O127: H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 73, 5183-5188.
59. Mangell P, Nejdfors P, Wang M, et al. (2002) Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci 47, 511-516.
60. Michail S & Abernathy F (2002) Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J Pediatr Gastroenterol Nutr 35, 350-355.
61. Parassol N, Freitas M, Thoreux K, et al. (2005) Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 156, 256-262.
62. Wells JM, Rossi O, Meijerink M, et al. (2011) Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 108, 4607-4614.
63. Everard A, Geurts L, Caesar R, et al. (2014) Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 5, 5648.
64. Cash HL, Whitham CV, Behrendt CL, et al. (2006) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313, 1126-1130.
65. El Aidy S, van Baarlen P, Derrien M, et al. (2012) Temporal and spatial interplay of microbiota and intestinal mucosa drive establishment of immune homeostasis in conventionalized mice. Mucosal Immunol 5, 567-579.
66. Putsep K, Axelsson LG, Boman A, et al. (2000) Germ-free and colonized mice generate the same products from enteric prodefensins. J Biol Chem 275, 40478-40482.
67. Hase K, Eckmann L, Leopard JD, et al. (2002) Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 70, 953-963.
68. Paolillo R, Carratelli CR, Sorrentino S, et al. (2009) Immuno-modulatory effects of Lactobacillus plantarum on human colon cancer cells. Int Immunopharmacol 9, 1265-1271.
69. Habil N, Abate W, Beal J, et al. (2014) Heat-killed probiotic bacteria differentially regulate colonic epithelial cell production of human beta-defensin-2: dependence on inflammatory cytokines. Benef Microbes 5, 483-495.
70. Wang G, Feng Y, Wang Y, et al. (2003) [Bifidobacterium cell wall proteins induced beta-defensin 2 mRNA expression in human intestinal epithelial cells]. J Sichuan Univ Sci Ed 34, 622-624.
71. Wehkamp J, Harder J, Wehkamp K, et al. (2004) NF-kB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72, 5750-5758.
72. McGuckin MA, Linden SK, Sutton P, et al. (2011) Mucin dynamics and enteric pathogens. Nat Rev Microbiol 9, 265-278.
73. Mack DR, Ahrne S, Hyde L, et al. (2003) Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52, 827-833.
74. Mack DR, Michail S, Wei S, et al. (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276, G941-G950.
75. Smirnova MG, Guo L, Birchall JP, et al. (2003) LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol 221, 42-49.
76. Cani PD, Possemiers S, Van de Wiele T, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103.
77. Cani PD, Amar J, Iglesias MA, et al. (2007) Metabolic endo-toxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772.
78. Wellen KE & Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115, 1111-1119.
79. Wellen KE & Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112, 1785-1788.
80. Laugerette F, Vors C, Geloen A, et al. (2011) Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 22, 53-59.
81. Erridge C, Attina T, Spickett CM, et al. (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 1286-1292.
82. Cani PD, Bibiloni R, Knauf C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481.
83. Cani PD, Neyrinck AM, Fava F, et al. (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50, 2374-2383.
84. Ley RE, Backhed F, Turnbaugh P, et al. (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102, 11070-11075.
85. Turnbaugh PJ, Backhed F, Fulton L, et al. (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213-223.
86. Waldram A, Holmes E, Wang Y, et al. (2009) Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res 8, 2361-2375.
87. Cani PD & Delzenne NM (2009) Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 9, 737-743.
88. Wang ZT, Yao YM, Xiao GX, et al. (2004) Risk factors of development of gut-derived bacterial translocation in thermally injured rats. World J Gastroenterol 10, 1619-1624.
89. Wang Z, Xiao G, Yao Y, et al. (2006) The role of bifido-bacteria in gut barrier function after thermal injury in rats. J Trauma 61, 650-657.
90. Griffiths EA, Duffy LC, Schanbacher FL, et al. (2004) In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 49, 579-589.
91. Zhang W, Gu Y, Chen Y, et al. (2010) Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. Eur J Gastro-enterol Hepatol 22, 1481-1486.
92. Wang H, Yu M, Ochani M, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421, 384-388.
93. Muccioli GG, Naslain D, Backhed F, et al. (2010) The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 6, 392.
94. Pachikian BD, Neyrinck AM, Deldicque L, et al. (2010) Changes in intestinal bifidobacteria levels are associated with the inflammatory response in magnesium-deficient mice. J Nutr 140, 509-514.
95. Everard A, Lazarevic V, Derrien M, et al. (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775-2786.
96. Delzenne NM & Cani PD (2011) Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 11, 154-159.
97. Delzenne NM & Cani PD (2011) Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 31, 15-31.
98. Delzenne NM, Neyrinck AM, Backhed F, et al. (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 9, 639-646.
99. Cani PD & Delzenne NM (2011) The gut microbiome as therapeutic target. Pharmacol Ther 130, 202-212.
100. Parnell JA & Reimer RA (2009) Weight loss during oligo-fructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89, 1751-1759.
101. Malaguarnera M, Vacante M, Antic T, et al. (2012) Bifido-bacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57, 545-553.
102. Dewulf EM, Cani PD, Claus SP, et al. (2012) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112-1121.
103. Cani PD & Van Hul M (2015) Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr Opin Biotechnol 32, 21-27.
104. Yun SI, Park HO & Kang JH (2009) Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 107, 1681-1686.
105. Kang JH, Yun SI & Park HO (2010) Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol 48, 712-714.
106. Takemura N, Okubo T & Sonoyama K (2010) Lactobacillus plantarum strain no. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med (Maywood) 235, 849-856.
107. Aronsson L, Huang Y, Parini P, et al. (2010) Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS ONE 5, e13087.
108. Arora T, Anastasovska J, Gibson G, et al. (2012) Effect of Lactobacillus acidophilus NCDC 13 supplementation on the progression of obesity in diet induced obese mice. Br J Nutr 108, 1382-1389.
109. Naito E, Yoshida Y, Makino K, et al. (2011) Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 110, 650-657.
110. Kadooka Y, Sato M, Imaizumi K, et al. (2010) Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 64, 636-643.
111. Kadooka Y, Sato M, Ogawa A, et al. (2013) Effect of Lacto-bacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr 110, 1696-1703.
112. Jung SP, Lee KM, Kang JH, et al. (2013) Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 34, 80-89.
113. Luoto R, Kalliomaki M, Laitinen K, et al. (2010) The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes 34, 1531-1537.
114. Angelakis E, Bastelica D, Ben Amara A, et al. (2012) An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog 52, 61-68.
115. An HM, Park SY, Lee do K, et al. (2011) Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 10, 116.
116. Chen JJ, Wang R, Li XF, et al. (2011) Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp Biol Med (Maywood) 236, 823-831.
117. Amar J, Chabo C, Waget A, et al. (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3, 559-572.
118. Collado MC, Meriluoto J & Salminen S (2007) Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 45, 454-460.
119. Putaala H, Salusjarvi T, Nordstrom M, et al. (2008) Effect of four probiotic strains and Escherichia coli O157: H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol 159, 692-698.
120. Everard A, Belzer C, Geurts L, et al. (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110, 9066-9071.
121. Shin NR, Lee JC, Lee HY, et al. (2013) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727-735.
122. Neu J & Walker WA (2011) Necrotizing enterocolitis. N Engl J Med 364, 255-264.
123. Ganguli K & Walker WA (2011) Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol 45, S133-S138.
124. AlFaleh K & Anabrees J (2014) Probiotics for prevention of necrotizing enterocolitis in preterm infants. The Cochrane Database of Systematic Reviews 2014, issue 16, CD005496.
125. Deshpande G, Rao S, Patole S, et al. (2010) Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 125, 921-930.
126. Mihatsch WA (2011) What is the power of evidence recommending routine probiotics for necrotizing enterocolitis prevention in preterm infants? Curr Opin Clin Nutr Metab Care 14, 302-306.
127. Mihatsch WA, Braegger CP, Decsi T, et al. (2012) Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr 31, 6-15.
128. Anand RJ, Leaphart CL, Mollen KP, et al. (2007) The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. Shock 27, 124-133.
129. Emami CN, Petrosyan M, Giuliani S, et al. (2009) Role of the host defense system and intestinal microbial flora in the pathogenesis of necrotizing enterocolitis. Surg Infect (Larchmt) 10, 407-417.
130. Hunter CJ, Upperman JS, Ford HR, et al. (2008) Understanding the susceptibility of the premature infant to necro-tizing enterocolitis (NEC). Pediatr Res 63, 117-123.
131. Levy O (2007) Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7, 379-390.
132. Neu J (2007) Gastrointestinal development and meeting the nutritional needs of premature infants. Am J Clin Nutr 85, 629S-634S.
133. Sherman MP (2010) New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention. Clin Perinatol 37, 565-579.
134. Sharma R & Tepas JJ III (2010) Microecology, intestinal epithelial barrier and necrotizing enterocolitis. Pediatr Surg Int 26, 11-21.
135. Agarwal R, Sharma N, Chaudhry R, et al. (2003) Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates. J Pediatr Gastroenterol Nutr 36, 397-402.
136. Chrzanowska-Liszewska D, Seliga-Siwecka J & Kornacka MK (2012) The effect of Lactobacillus rhamnosus GG supplemented enteral feeding on the microbiotic flora of preterm infants-double blinded randomized control trial. Early Hum Dev 88, 57-60.
137. Costalos C, Skouteri V, Gounaris A, et al. (2003) Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum Dev 74, 89-96.
138. Manzoni P, Mostert M, Leonessa ML, et al. (2006) Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 42, 1735-1742.
139. Manzoni P (2007) Use of Lactobacillus casei subspecies rhamnosus GG and gastrointestinal colonization by Candida species in preterm neonates. J Pediatr Gastroenterol Nutr 45, S190-S194.
140. Romeo MG, Romeo DM, Trovato L, et al. (2011) Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 31, 63-69.
141. Rouge C, Piloquet H, Butel MJ, et al. (2009) Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 89, 1828-1835.
142. Underwood MA, Salzman NH, Bennett SH, et al. (2009) A randomized placebo-controlled comparison of 2 prebiotic/ probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr 48, 216-225.
143. Indrio F, Riezzo G, Raimondi F, et al. (2008) The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 152, 801-806.
144. Stratiki Z, Costalos C, Sevastiadou S, et al. (2007) The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. Early Hum Dev 83, 575-579.
145. Mohan R, Koebnick C, Schildt J, et al. (2006) Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol 44, 4025-4031.
146. Mohan R, Koebnick C, Schildt J, et al. (2008) Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 64, 418-422.
147. Fak F, Ahrne S, Linderoth A, et al. (2008) Age-related effects of the probiotic bacterium Lactobacillus plantarum 299v on gastrointestinal function in suckling rats. Dig Dis Sci 53, 664-671.
148. Preidis GA, Saulnier DM, Blutt SE, et al. (2012) Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. FASEB J 26, 1960-1969.
149. Siggers RH, Siggers J, Boye M, et al. (2008) Early administration of probiotics alters bacterial colonization and limits diet-induced gut dysfunction and severity of necrotizing enterocolitis in preterm pigs. J Nutr 138, 1437-1444.
150. Lee DJ, Drongowski RA, Coran AG, et al. (2000) Evaluation of probiotic treatment in a neonatal animal model. Pediatr Surg Int 16, 237-242.
151. Sherman MP, Bennett SH, Hwang FF, et al. (2004) Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals 17, 285-289.
152. McVay MR, Boneti C, Habib CM, et al. (2008) Formula fortified with live probiotic culture reduces pulmonary and gastrointestinal bacterial colonization and translocation in a newborn animal model. J Pediatr Surg 43, 25-29.
153. Gareau MG, Jury J, MacQueen G, et al. (2007) Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 56, 1522-1528.
154. Isolauri E, Kaila M, Arvola T, et al. (1993) Diet during rota-virus enteritis affects jejunal permeability to macromolecules in suckling rats. Pediatr Res 33, 548-553.
155. Isolauri E, Majamaa H, Arvola T, et al. (1993) Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 105, 1643-1650.
156. Terpend K, Blaton MA, Candalh C, et al. (1999) Intestinal barrier function and cow's milk sensitization in guinea pigs fed milk or fermented milk. J Pediatr Gastroenterol Nutr 28, 191-198.
157. Caplan MS, Miller-Catchpole R, Kaup S, et al. (1999) Bifido-bacterial supplementation reduces the incidence of necro-tizing enterocolitis in a neonatal rat model. Gastroenterology 117, 577-583.
158. Liu Y, Fatheree NY, Mangalat N, et al. (2012) Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 302, G608-G617.
159. Good M, Sodhi CP, Ozolek JA, et al. (2014) Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. Am J Physiol Gastrointest Liver Physiol 306, G1021-G1032.
160. Khailova L, Dvorak K, Arganbright KM, et al. (2009) Bifido-bacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 297, G940-G949.
161. Underwood MA, Kananurak A, Coursodon CF, et al. (2012) Bifidobacterium bifidum in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. Pediatr Res 71, 546-551.
162. Lin PW, Nasr TR, Berardinelli AJ, et al. (2008) The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res 64, 511-516.
163. Hunter CJ, Williams M, Petrosyan M, et al. (2009) Lacto-bacillus bulgaricus prevents intestinal epithelial cell injury caused by Enterobacter sakazakii-induced nitric oxide both in vitro and in the newborn rat model of necrotizing entero-colitis. Infect Immun 77, 1031-1043.
164. Goncalves FLL, Soares LMM, Figueira RL, et al. (2015) Evaluation of the expression of I-FABP and L-FABP in a necro-tizing enterocolitis model after the use of Lactobacillus acidophilus. J Pediatr Surg 50, 543-549.
165. Liu Y, Fatheree NY, Mangalat N & Rhoads JM (2010) Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299, G1087-G1096.
166. Cilieborg MS, Thymann T, Siggers R, et al. (2011) The incidence of necrotizing enterocolitis is increased following pro-biotic administration to preterm pigs. J Nutr 141, 223-230.
167. Guenther K, Straube E, Pfister W, et al. (2010) Severe sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J 29, 188-189.
168. Land MH, Rouster-Stevens K, Woods CR, et al. (2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115, 178-181.
169. Levy RL, Olden KW, Naliboff BD, et al. (2006) Psychosocial aspects of the functional gastrointestinal disorders. Gastro-enterology 130, 1447-1458.
170. Koloski NA, Talley NJ & Boyce PM (2002) Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol 97, 2290-2299.
171. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastro-enterology 133, 24-33.
172. Rajilic-Stojanovic M, Biagi E, Heilig HGHJ, et al. (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792-1801.
173. Chassard C, Dapoigny M, Scott KP, et al. (2012) Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 35, 828-838.
174. Carroll IM, Ringel-Kulka T, Siddle JP, et al. (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24, 521-530.
175. Jeffery IB, OToole PW, Ohman L, et al. (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997-1006.
176. Sundin J, Rangel I, Fuentes S, et al. (2015) Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 41, 342-351.
177. Tojo GR, Suarez GA, Ruas MP, et al. (2014) [Irritable Bowel Syndrome; gut microbiota and probiotic therapy]. Nutr Hosp 31, 83-88.
178. Lee KN & Lee OY (2014) Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 20, 8886.
179. Theodorou V, it-Belgnaoui A, Agostini S, et al. (2014) Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes 5, 430-436.
180. Hyland NP, Quigley EMM & Brint E (2014) Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 20, 8859.
181. Nebot-Vivinus M, Harkat C, Bzioueche H, et al. (2014) Multispecies probiotic protects gut barrier function in experimental models. World J Gastroenterol 20, 6832.
182. Laval L, Martin R, Natividad JN, et al. (2015) Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 6, 1-6839.
183. Wang H, Gong J, Wang W, et al. (2014) Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model. PLOS ONE 9, e90153.
184. Da Silva S, Robbe-Masselot C, it-Belgnaoui A, et al. (2014) Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. Am J Physiol Gastrointest Liver Physiol 307, G420-G429.
185. Agostini S, Goubern M, Tondereau V, et al. (2012) A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 24, 376-e172.
186. Koenig J & Brummer RJ (2014) Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. BenefMicrobes 5, 247-261.
187. Whelan K (2011) Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 14, 581-587.
188. Moayyedi P, Ford AC, Talley NJ, et al. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59, 325-332.
189. Hoveyda N, Heneghan C, Mahtani KR, et al. (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9, 15.
190. Gibson GR, Brummer RJ, Isolauri E, et al. (2011) The design of probiotic studies to substantiate health claims. Gut Microbes 2, 299-305.
191. Clarke G, Cryan JF, Dinan TG, et al. (2012) Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 35, 403-413.
192. Saulnier DM, Riehle K, Mistretta T, et al. (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141, 1782-1791.
193. Vanhoutvin SALW, Troost FJ, Kilkens TOC, et al. (2009) The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 21, 952-e76.
194. MacDonald TT, Monteleone I, Fantini MC, et al. (2011) Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140, 1768-1775.
195. Pastorelli L, De Salvo C, Mercado JR, et al. (2013) Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 4, 280.
196. Beaurepaire C, Smyth D & McKay DM (2009) Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 29, 133-144.
197. Gibson PR (2004) Increased gut permeability in Crohn's disease: is TNF the link? Gut 53, 1724-1725.
198. Prasad S, MingrinoR, Kaukinen K, et al. (2005) Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85, 1139-1162.
199. Biancheri P, Di Sabatino A, Corazza GR, et al. (2013) Proteases and the gut barrier. Cell Tissue Res 351, 269-280.
200. Prantera C, Scribano ML, Falasco G, et al. (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG Gut 51, 405-409.
201. Marteau P, Lemann M, Seksik P, et al. (2006) Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55, 842-847.
202. Van Gossum A, Dewit O, Louis E, et al. (2007) Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 13, 135-142.
203. Chermesh I, Tamir A, Reshef R, et al. (2007) Failure of Syn-biotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52, 385-389.
204. Steed H, Macfarlane GT, Blackett KL, et al. (2010) Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 32, 872-883.
205. Ghouri YA, Richards DM, Rahimi EF, et al. (2014) Systematic review of randomized controlled trials of probiotics, pre-biotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7, 473.
206. Whelan K & Quigley EMM (2013) Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29, 184-189.
207. Kruis W, Schutz E, Fric P, et al. (1997) Double-blind comparison of an oral Escherichia coli preparation and mesala-zine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11, 853-858.
208. Veerappan GR, Betteridge J & Young PE (2012) Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 14, 324-333.
209. Yan F, Cao H, Cover TL, et al. (2011) Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 121, 2242.
210. Toumi R, Abdelouhab K, Rafa H, et al. (2013) Beneficial role of the probiotic mixture Ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis. Immunopharmacol Immunotoxicol 35, 403-409.
211. Mennigen R, Nolte K, Rijcken E, et al. (2009) Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296, G1140-G1149.
212. Srutkova D, Schwarzer M, Hudcovic T, et al. (2015) Bifido-bacterium longum CCM 7952 promotes epithelial barrier function and prevents acute DSS-induced colitis in strictly strain-specific manner. PLOS ONE 10, e0134050.
213. Ahl D, Liu H, Schreiber O, et al. (2016) Lactobacillus reuteri increases mucus thickness and ameliorates dextran sulphate sodium-induced colitis in mice. Acta Physiol (Oxf) 217, 300-310.
214. Ewaschuk JB, Diaz H, Meddings L, et al. (2008) Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 295, G1025-G1034.
215. Yan F, Liu L, Dempsey PJ, et al. (2013) A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. J Biol Chem 288, 30742-30751.
216. Rescigno M (2011) The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol 32, 256-264.
217. Atarashi K, Tanoue T, Shima T, et al. (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337-341.
218. Atarashi K, Tanoue T, Oshima K, et al. (2013) Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232-236.
219. Furusawa Y, Obata Y, Fukuda S, et al. (2014) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446-450.
220. Khoruts A, Dicksved J, Jansson JK, et al. (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44, 354-360.
221. Borody TJ & Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9, 88-96.
222. Borody TJ, Warren EF, Leis S, et al. (2003) Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastro-enterol 37, 42-47.
223. Vrieze A, Van Nood E, Holleman F, et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastro-enterology 143, 913-916.
224. Spiller RC, Jenkins D, Thornley JP, et al. (2000) Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47, 804-811.
225. Panzer AR & Lynch SV (2015) Influence and effect of the human microbiome in allergy and asthma. Curr Opin Rheumatol 27, 373-380.
226. Rosenfeldt V, Benfeldt E, Valerius NH, et al. (2004) Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 145, 612-616.
227. McNaught CE, Woodcock NP, Anderson ADG, et al. (2005) A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 24, 211-219.
228. Klaenhammer TR, Kleerebezem M, Kopp MV, et al. (2012) The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol 12, 728-734.